Persistent and novel changes in plasma microRNA profiles in patients with non-small cell lung cancer following tumour resection.

IF 4 2区 医学 Q2 ONCOLOGY
Translational lung cancer research Pub Date : 2025-03-31 Epub Date: 2025-03-27 DOI:10.21037/tlcr-24-626
Maria Sromek, Maciej Głogowski, Magdalena Chechlińska, Mariusz Kulińczak, Michalina Zajdel, Natalia Żeber-Lubecka, Aneta Bałabas, Łukasz M Szafron, Maria Kulecka, Jan K Siwicki
{"title":"Persistent and novel changes in plasma microRNA profiles in patients with non-small cell lung cancer following tumour resection.","authors":"Maria Sromek, Maciej Głogowski, Magdalena Chechlińska, Mariusz Kulińczak, Michalina Zajdel, Natalia Żeber-Lubecka, Aneta Bałabas, Łukasz M Szafron, Maria Kulecka, Jan K Siwicki","doi":"10.21037/tlcr-24-626","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers, the leading cause of cancer mortality. microRNAs (miRNA, miR) have emerged as important components of carcinogenesis and promising biomarkers. We aimed to analyse global plasma miRs in NSCLC patients before and at least one year after tumour resection.</p><p><strong>Methods: </strong>Plasma was collected from the peripheral blood of 24 donors without cancer and of NSCLC patients before surgery (n=36) and at least 1 year after surgery (n=12). Next-generation sequencing (NGS)-based miR profiling was performed. Patients were followed-up for 4 to 12 years after surgery to assess disease recurrence.</p><p><strong>Results: </strong>Untreated NSCLC patients exhibited significant changes in plasma miR levels compared to cancer-free donors (48 up- and 17 down-regulated miRs). miR profiles in patients with adenocarcinoma (ADC) (n=18) and squamous cell carcinoma (SCC) significantly differed (16 and 86 miRs up-, and 15 and 16 miRs down-regulated, respectively). A subset of pre-surgery deregulated miRs was found to be associated with recurrence (49 miRs). Six miRs were shown to have independent prognostic value. After tumour resection, some pre-surgery miR alterations returned to control levels (18 miRs), some others persisted (27 miRs), while also novel plasma miR changes emerged (75 miRs) in patients with no clinical evidence of recurrence.</p><p><strong>Conclusions: </strong>Untreated NSCLC patients present deregulated plasma miRs, some of which may have a potential of prognostic markers. After tumour excision plasma miR profiles change, some miR levels normalise, some changes persist and novel miR changes are observed despite no clinical symptoms of recurrence. Plasma miR profiles in NSCLC patients may suggest systemic abnormalities predisposing to lung cancer and/or reflect a systemic response to pre-cancer/dormant cancer cells.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"677-706"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000959/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-626","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers, the leading cause of cancer mortality. microRNAs (miRNA, miR) have emerged as important components of carcinogenesis and promising biomarkers. We aimed to analyse global plasma miRs in NSCLC patients before and at least one year after tumour resection.

Methods: Plasma was collected from the peripheral blood of 24 donors without cancer and of NSCLC patients before surgery (n=36) and at least 1 year after surgery (n=12). Next-generation sequencing (NGS)-based miR profiling was performed. Patients were followed-up for 4 to 12 years after surgery to assess disease recurrence.

Results: Untreated NSCLC patients exhibited significant changes in plasma miR levels compared to cancer-free donors (48 up- and 17 down-regulated miRs). miR profiles in patients with adenocarcinoma (ADC) (n=18) and squamous cell carcinoma (SCC) significantly differed (16 and 86 miRs up-, and 15 and 16 miRs down-regulated, respectively). A subset of pre-surgery deregulated miRs was found to be associated with recurrence (49 miRs). Six miRs were shown to have independent prognostic value. After tumour resection, some pre-surgery miR alterations returned to control levels (18 miRs), some others persisted (27 miRs), while also novel plasma miR changes emerged (75 miRs) in patients with no clinical evidence of recurrence.

Conclusions: Untreated NSCLC patients present deregulated plasma miRs, some of which may have a potential of prognostic markers. After tumour excision plasma miR profiles change, some miR levels normalise, some changes persist and novel miR changes are observed despite no clinical symptoms of recurrence. Plasma miR profiles in NSCLC patients may suggest systemic abnormalities predisposing to lung cancer and/or reflect a systemic response to pre-cancer/dormant cancer cells.

非小细胞肺癌患者肿瘤切除后血浆microRNA谱的持续和新的变化。
背景:非小细胞肺癌(NSCLC)占肺癌的80%,是癌症死亡的主要原因。microRNAs (miRNA, miR)已成为致癌的重要组成部分和有前途的生物标志物。我们的目的是分析非小细胞肺癌患者在肿瘤切除前和至少一年后的全球血浆miRs。方法:采集24例无癌供体和非小细胞肺癌患者术前(n=36)和术后至少1年(n=12)外周血血浆。进行基于下一代测序(NGS)的miR分析。术后随访4 - 12年以评估疾病复发情况。结果:与无癌供者相比,未经治疗的NSCLC患者的血浆miR水平发生了显著变化(48例miR上调,17例miR下调)。腺癌(ADC) (n=18)和鳞状细胞癌(SCC)患者的miR谱差异显著(分别有16和86个miRs上调,15和16个miRs下调)。发现术前失调的miRs子集与复发相关(49个miRs)。6个mir被证明具有独立的预后价值。肿瘤切除后,一些术前miR改变恢复到控制水平(18 miRs),另一些持续(27 miRs),而在没有临床复发证据的患者中也出现了新的血浆miR改变(75 miRs)。结论:未经治疗的非小细胞肺癌患者存在血浆miRs失调,其中一些可能具有潜在的预后标志物。肿瘤切除后血浆miR谱改变,一些miR水平恢复正常,一些变化持续存在,尽管没有复发的临床症状,但仍观察到新的miR变化。非小细胞肺癌患者的血浆miR谱可能提示易患肺癌的全身异常和/或反映了对癌前/休眠癌细胞的全身反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
2.50%
发文量
137
期刊介绍: Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信